# Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

> **NCT05541445** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05541445
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541445, "Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05541445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*